JP7843113B2 - Ａｐｒｉｌ－ｔａｃｉ間相互作用のモジュレーターを用いた制御性ｔ細胞、制御性ｂ細胞、及び免疫応答の調節方法 - Google Patents

Ａｐｒｉｌ－ｔａｃｉ間相互作用のモジュレーターを用いた制御性ｔ細胞、制御性ｂ細胞、及び免疫応答の調節方法

Info

Publication number
JP7843113B2
JP7843113B2 JP2019569878A JP2019569878A JP7843113B2 JP 7843113 B2 JP7843113 B2 JP 7843113B2 JP 2019569878 A JP2019569878 A JP 2019569878A JP 2019569878 A JP2019569878 A JP 2019569878A JP 7843113 B2 JP7843113 B2 JP 7843113B2
Authority
JP
Japan
Prior art keywords
treg
breg
cancer
cells
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019569878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524149A5 (https=
JP2020524149A (ja
Inventor
ケネス シー． アンダーソン，
ユー－ズー タイ，
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2020524149A publication Critical patent/JP2020524149A/ja
Publication of JP2020524149A5 publication Critical patent/JP2020524149A5/ja
Application granted granted Critical
Publication of JP7843113B2 publication Critical patent/JP7843113B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019569878A 2017-06-20 2018-06-20 Ａｐｒｉｌ－ｔａｃｉ間相互作用のモジュレーターを用いた制御性ｔ細胞、制御性ｂ細胞、及び免疫応答の調節方法 Active JP7843113B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762522167P 2017-06-20 2017-06-20
US62/522,167 2017-06-20
US201762573264P 2017-10-17 2017-10-17
US62/573,264 2017-10-17
US201862677265P 2018-05-29 2018-05-29
US62/677,265 2018-05-29
PCT/US2018/038490 WO2018236995A2 (en) 2017-06-20 2018-06-20 Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction

Publications (3)

Publication Number Publication Date
JP2020524149A JP2020524149A (ja) 2020-08-13
JP2020524149A5 JP2020524149A5 (https=) 2021-07-29
JP7843113B2 true JP7843113B2 (ja) 2026-04-09

Family

ID=64735842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019569878A Active JP7843113B2 (ja) 2017-06-20 2018-06-20 Ａｐｒｉｌ－ｔａｃｉ間相互作用のモジュレーターを用いた制御性ｔ細胞、制御性ｂ細胞、及び免疫応答の調節方法

Country Status (7)

Country Link
US (1) US12005073B2 (https=)
EP (1) EP3642243A4 (https=)
JP (1) JP7843113B2 (https=)
CN (1) CN110945030A (https=)
AU (1) AU2018289493B2 (https=)
CA (1) CA3064632A1 (https=)
WO (1) WO2018236995A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11435370B2 (en) * 2017-01-16 2022-09-06 Shimadzu Corporation Data analying device and program for data analysis
EP3642243A4 (en) 2017-06-20 2021-04-28 Dana-Farber Cancer Institute, Inc. METHOD OF MODULATING REGULATORY T-CELLS, REGULATORY B-CELLS AND IMMUNE RESPONSIBILITIES USING MODULATORS OF APRIL-TACI INTERACTION
EP3887548A1 (en) * 2018-11-30 2021-10-06 GBG Forschungs GmbH Method for predicting the response to cancer immunotherapy in cancer patients
KR20220016188A (ko) * 2019-05-31 2022-02-08 메디뮨 엘엘씨 병용 요법
JP7748393B2 (ja) 2020-05-08 2025-10-02 アルパイン イミューン サイエンシズ インコーポレイテッド Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法
US20230310500A1 (en) * 2020-09-03 2023-10-05 Techno Craft Corporation Ltd. Use of Immune Killer Cell Against Circulating Tumor Cells in Solid Tumor Treatment
CN113368262A (zh) * 2020-09-03 2021-09-10 上海易慕峰生物科技有限公司 通过实体肿瘤转移动物模型获取中间结果的方法
US20230250042A1 (en) * 2020-09-29 2023-08-10 Purdue Research Foundation Curcusone diterpenoids and uses thereof
CN113278619B (zh) * 2021-07-19 2021-10-15 广东省农业科学院动物科学研究所 双sgRNA、基因敲除载体、基因敲除STING基因的猪成纤维细胞系及其构建方法
CN114147343B (zh) * 2021-12-08 2024-08-16 西安中科微精光子科技股份有限公司 一种激光加工方法、系统及计算机存储介质
CN118126196B (zh) * 2024-03-06 2024-08-16 中国医学科学院基础医学研究所 一种具有包含taci融合蛋白的基因工程化外泌体及其制备方法和应用
CN120843525B (zh) * 2025-09-23 2025-12-09 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 特异结合人april的中和核酸适体及其在抑制抗体分泌中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011047121A1 (en) 2009-10-14 2011-04-21 Schering Corporation April antagonists and methods of use
WO2016110587A1 (en) 2015-01-09 2016-07-14 Aduro Biotech Holdings, Europe B.V. Altered april binding antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086018A1 (en) * 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
CN101323643B (zh) * 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
WO2010075249A2 (en) * 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN102585016B (zh) 2012-03-06 2014-06-04 江苏健德生物药业有限公司 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
EP3642243A4 (en) 2017-06-20 2021-04-28 Dana-Farber Cancer Institute, Inc. METHOD OF MODULATING REGULATORY T-CELLS, REGULATORY B-CELLS AND IMMUNE RESPONSIBILITIES USING MODULATORS OF APRIL-TACI INTERACTION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011047121A1 (en) 2009-10-14 2011-04-21 Schering Corporation April antagonists and methods of use
WO2016110587A1 (en) 2015-01-09 2016-07-14 Aduro Biotech Holdings, Europe B.V. Altered april binding antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Blood, 2016, Vol. 128, No. 22, p. 2112, http://doi.org/10.1182/blood.V128.22.2112.2112
NATURE COMMUNICATIONS, 2015, Vol. 6, No. 5997, pp. 1-16, DOI: 10.1038/ncomms6997
Nature Immunology, 2000, Vol. 1, No. 3, pp. 252-256

Also Published As

Publication number Publication date
WO2018236995A3 (en) 2019-01-31
EP3642243A2 (en) 2020-04-29
WO2018236995A2 (en) 2018-12-27
AU2018289493B2 (en) 2025-07-03
CA3064632A1 (en) 2018-12-27
JP2020524149A (ja) 2020-08-13
CN110945030A (zh) 2020-03-31
US12005073B2 (en) 2024-06-11
AU2018289493A1 (en) 2019-12-12
EP3642243A4 (en) 2021-04-28
US20210113605A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
JP7843113B2 (ja) Ａｐｒｉｌ－ｔａｃｉ間相互作用のモジュレーターを用いた制御性ｔ細胞、制御性ｂ細胞、及び免疫応答の調節方法
US20250108115A1 (en) Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof
JP2023529026A (ja) Ｍｈｃ－ｉ発現を調節するための方法及びその免疫療法の使用
US20200108066A1 (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
EP4093513A1 (en) Uses of biomarkers for improving immunotherapy
US11740242B2 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
WO2018148378A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
AU2019227641B2 (en) Methods for treating cancer using combinations of anti-BTNL2 and immune checkpoint blockade agents
US12109266B2 (en) Modulating gabarap to modulate immunogenic cell death
US11852631B2 (en) Biomarkers predictive of anti-immune checkpoint response
AU2020358867A1 (en) Anti-KIR3DL3 antibodies and uses thereof
US20220289854A1 (en) Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
HK40028190A (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240401

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260323

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260330

R150 Certificate of patent or registration of utility model

Ref document number: 7843113

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150